About Everest Biolabs
We’re dedicated to reaching excellence in EV research by relentless focus on high-quality, easy-to-use tools for exosome and EV isolation and analytics. Our solutions are designed to enhance researchers’ daily workflows, from foundational EV isolation to advanced analytics, enabling groundbreaking discoveries. With a vision to unlock the potential of EVs in clinical applications, we keep ‘science first’ while fostering innovation and integrity in everything we do. Based in Boston, MA we’re here to elevate exosome research at every step.
George is a visionary biomedical entrepreneur with a strong foundation in life science analytical tools and business leadership. His experience leading innovation and growth in the life sciences makes him uniquely positioned to drive Everest Biolabs toward success.
Previous Experiences: George co-founded NanoView Biosciences, where he developed analytical platforms for characterization of nanoparticles like exosomes and viral vectors, leading to its acquisition by Unchained Labs in 2022. He holds a Ph.D. in Biomedical Engineering from Boston University and has executive education credentials from Stanford and MIT. His contributions to advanced life science tools are reflected in numerous publications.
David is a dynamic life sciences entrepreneur and engineer with expertise in startup leadership and biotechnology innovation. His operational acumen and technical depth underpin the company’s transformative impact on exosome research.
Previous Experiences: David co-founded NanoView Biosciences, where he led its growth through product innovation, venture funding, and global expansion before its acquisition. At Unchained Labs, he launched pioneering small-particle detection tools. With a Ph.D. in Electrical Engineering from Boston University and dual undergraduate degrees in Electrical Engineering and Economics from UC San Diego, David’s career spans impactful roles in research, teaching, and industry leadership.
Dima is a scientist with over a decade of experience in developing new technologies for the isolation and characterization of extracellular vesicles (EVs).
Previous Experiences: Dima serves as Senior Staff Scientist at the Wyss Institute for Biologically Inspired Engineering at Harvard University, where he works with David Walt’s lab to develop new tools for biomarker discovery. He earned a Ph.D. in Biochemistry from Harvard University, co-advised by George Church and Aviv Regev, where his research focused on characterizing RNA in EVs. Previously, Dima was also one of the first employees at Exosome Diagnostics, a cancer liquid biopsy company acquired by Bio-Techne. Outside of his academic work, Dima has also advised several venture capital firms and life science investors on the evaluation of new technologies for diagnostics and therapeutics.
Tal is a pioneering researcher with deep expertise in diagnostics, neurodegenerative diseases, and single-molecule sensing. Her leadership in innovative research drives Everest Biolabs’ advancements in extracellular vesicle technology.
Previous Experiences: Tal was a Postdoctoral Researcher at Harvard’s Wyss Institute, focusing on molecular diagnostics and biosensors. She earned her Ph.D. in Biomedical Engineering from the Technion – Israel Institute of Technology, contributing significant advancements in electro-optical sensing in nanopores. Tal has received prestigious awards for her PhD and postdoctoral studies, and authored numerous publications in nanotechnology.
David is a world-renowned academic and entrepreneur, with decades of experience pioneering innovations in biotechnology and medical diagnostics. His expertise helps guide Everest Biolabs’ scientific direction and strategic growth.
Previous Experiences: David is the Hansjörg Wyss Professor of Biologically Inspired Engineering at Harvard Medical School and a core faculty member at the Wyss Institute. He co-founded several successful biotech companies, including Illumina and Quanterix, and has played key roles in developing transformative diagnostic technologies. David holds a Ph.D. in Chemical Biology from Stony Brook University and a B.S. in Chemistry from the University of Michigan.
Paul is a seasoned executive and investor with extensive experience in biotechnology, healthcare, and technology. His strategic leadership and investment expertise support Everest Biolabs’ long-term vision and operational growth.
Previous Experiences: Paul is the CEO of Liberty Lane Partners, a private investment firm, and co-founder of Perspecta Trust. He has held leadership roles such as President of MacAndrews & Forbes and Chairman of Thermo Fisher Scientific. Paul serves on the boards of multiple organizations, including Aptiv PLC, Amneal Pharmaceuticals, and Quanterix Corporation. He earned an MBA from Northwestern University and a Bachelor’s degree from the University of Michigan.
Dimitri is a seasoned leader in nanosciences and life sciences with exceptional expertise in market development and company growth. His strategic vision supports Everest Biolabs’ global business expansion.
Previous Experiences: Dimitri held key roles at NanoFCM and Izon Science, where he drove growth and standardized nanoparticle analysis methods. His leadership spans companies like Thermo Fisher Scientific and IDEX Corporation. Dimitri holds a Ph.D. in Chemistry from the University of Nottingham, with additional academic training in France and the UK.
Steven is an accomplished engineer and biologist specializing in instrumentation and biosensor development. His expertise in assay integration and manufacturing is pivotal to Everest Biolabs’ innovative product pipeline.
Previous Experiences: Steven has held leadership roles at General Fluidics Corporation, Unchained Labs, and NanoView Biosciences, focusing on diagnostic tool innovation. He earned a Ph.D. in Mechanical Engineering from Boston University, where he developed virus detection technologies. Steven’s contributions to healthcare diagnostics are reflected in his numerous publications.
